|
THE FEMALE HEALTH COMPANY REPORTS: GHANA orders One million female condoms for project expansion Order
continues increased availability for protection for women CHICAGO,
29 March 2001 – The Female Health Company
(OTC
Bulletin Board: FHCO) today announced that it
received an order from the United Nations Population Fund (UNFPA) for one
million Female Condoms for the Ministry of Health in Ghana, a country of
20 million people in West Africa. The
Ministry of Health of Ghana launched the female condom in May 2000 after
extensive strategic planning with the Joint United Nations Programme on
HIV/AIDS (UNAIDS), the United Nations Population Fund (UNFPA), the Ghana
Social Marketing Foundation, the Society for Women and AIDS in Africa (SWAA)
and the Female Health Company. The project has been guided by the new
UNAIDS/World Health Organization (WHO) publication, “The Female Condom:
A Guide for Planning and Programming.” The order doubles last years
purchase. “The
Female Condom project in Ghana is a superb example of a true partnership
between a national government, UN agencies, local non-governmental
organizations and a product manufacturer working together to deliver
HIV/AIDS prevention options to women and men. We believe that this
experience can serve as a model for other countries not only to distribute
the female condom but to plan strategically for more comprehensive AIDS
prevention programs that include prevention, care and treatment,” said
Dr. Mary Ann Leeper, president of the Female Health Company. “As
the global discussions focus on
drug treatments and vaccines, infection rates continue to rise. We must
not ignore significant tools for primary prevention that are today’s
best hope of reversing the rising tide of infection.
The work in Ghana as in many other countries of sub-Saharan Africa
show that women (and men) made aware of the Female Condom’s protective
potential, cry out for a method like this that they can control and use
themselves. This is especially crucial when the increase in infection
rates disproportionately affects young women in their 20s,” said Dr.
Leeper. “It is increasingly clear that a comprehensive AIDS programs
must combine accessible drug treatments with a strong prevention program
including both male and female condoms.” The
active participation of the Ghana Chapter of SWAA has played a
particularly important role in
helping to mobilise local women’s organizations and community groups to
educate about the importance of safer sex generally.
SWAA and FHC are co-sponsoring a workshop to explore the lessons
learned in Ghana, Senegal and elsewhere at SWAA’s bi-annual conference
scheduled to take place in Uganda from April 2 to 6. “We
are eager to share our experiences and assist other programs benefit from
our own experiences in launching and introducing the Female Condom,”
said Alice Sena Lamptey, the SWAA-Ghana coordinator. “Demand for the
Female Condom among both women and men continues to be incredibly strong,
and we are particularly excited the young women are responding to our
prevention message.” Ghana
is one of the initial countries to participate in the United Nation’s
International Partnership against AIDS in Africa (IPAA). IPAA is a coalition
of African countries, the United Nations, donor organizations, private
companies and community representatives, who have chosen to work together
to curtail the spread of HIV/AIDS in Africa, reduce its impact on human
suffering and halt the further decline of human, social and economic
development that HIV/AIDS is causing. “We
continue to work closely with the project partners in Ghana and elsewhere
to assist in developing the best possible comprehensive AIDS program as
part of the IPAA,” said Dr. Leeper. UNAIDS
supported studies show that when the Female Condom is available as an
option, there is a significant reduction in the incidence of sexually
transmitted disease (STD) compared to when only the male condom is
available. Additional research, recently published,
highlights that incorporating the Female Condom into prevention programs
can be cost saving as it reduces the number of unprotected sexual acts,
the incidence of STDs, and the costs related to treatment and care. The
Female Condom is the only product controlled by women that helps to
prevent STDs, including HIV/AIDS and unintended pregnancy.
The Female Condom is made of polyurethane, which is strong and
unlikely to rip or tear during use and unlikely to cause allergic
reactions. It is manufactured in a state of the art facility in London,
England. The
Female Health Company, based in Chicago, owns certain worldwide rights to
The Female Condomä,
including patents that have been issued in the United States, United
Kingdom, Japan, France, Italy, Germany, Spain, The People’s Republic of
China, Canada, New Zealand, South Korea and Australia. ### “Safe Harbor” Statement under the Private
Securities Litigation Reform Action of 1995: The
statements in this release which are not historical fact are
forward-looking statements based upon the Company’s current plans and
strategies, and reflect the Company’s current assessment of the risks
and uncertainties related to its business, including such things as
product demand and market acceptance; the economic and business
environment and the impact of governmental regulations, both in the United
States and abroad; the effects of competitive products and pricing
pressures; currency risks; capacity; efficiency and supply constraints;
and other risks detailed in the Company’s press releases, shareholder
communication and Securities and Exchange Commission filings. Actual
events affecting the Company and the impact of such events on the
Company’s operations may vary from those currently anticipated. For
more information, dial toll-free via fax 1-800-PRO-INFO, and enter company
code “FHCO.” Also, visit
the company’s web site, www.femalehealth.com. ###
For more information about the Female Health
Company, dial toll-free via fax,
Contacts:
Investors
Business / Product
Global Program
William R. Gargiulo, Jr.
Mary Ann Leeper, Ph.D. Mitchell
Warren 231.526.1244 312.280.1119 x223 845-353-8298 |